ABBOTT LABORATORIES
No SEC Form 4 filings for $ABT in the last 30 days.
Diamond Hill Capital’s Q1 2026 Large Cap Strategy investor letter cited Abbott Laboratories (ABT) after the company’s Q4 results and forward guidance, which the letter says were below expectations due to headwinds in Abbott’s nutrition business. ABT closed May 22, 2026 at $87.77; the stock fell 5.81% over one month and 33.43% over 52 weeks.
Abbott Laboratories is expanding its focus on digital health by introducing new cardiovascular diagnostics and wearable devices like its Lingo biomarker. This strategic shift aims to deepen customer relationships and drive long-term revenue growth, despite potential near-term pressures on margins from increased R&D and software investments. Investors are encouraged to monitor the adoption rates of these new technologies and how Abbott balances its digital health spending with existing product lines.
The article discusses factors hospitals should consider when purchasing pulsed field ablation systems due to the crowded market. It lists several companies offering these systems, including Boston Scientific, Abbott, Medtronic, Johnson & Johnson MedTech, and Kardium Inc. The piece is part of a series covering medical devices.
